tbuckley/cabot-search huggingface dataset:
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Authors: Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Min-Hee Ryu, John J. Park, Jee Hyun Kim, Yahua Zhong, Yiming Zhao, Mark Voskoboynik, Yongmei Yin, Kan Liu, Andreas Kaubisch, Caigang Liu, Jian Zhang, Shouman Wang, Seock-Ah Im, Vinod Ganju, Minal Barve, Hui Li, Changsheng Ye, Amitesh C. Roy, Li-Yuan Bai, Chia-Jui Yen, Shanzhi Gu, Yung-Chang Lin, Lingying Wu, Lequn Bao, Kaijing Zhao, Yu Shen, Shangyi Rong, Xiaoyu Zhu, Erwei Song
Journal: Journal of Clinical Oncology (2024)

PURPOSE SHR-A1811 is an antibody-drug conjugate composed of an anti–human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors. METHODS This global, multi-center, first-in-human, phase I trial was conducted at 33 centers. Patients who had HER2-expressing or mutated unresectable, advanced, or metastatic solid tumors and were refractory or intolerant to standard therapies were enrolled. SHR-A1811 was administered intravenously at doses ranging from 1.0 to 8.0 mg/kg once every 3 weeks. The primary end points were dose-limiting toxicity, safety, and the recommended phase II dose. RESULTS From September 7, 2020, to February 27, 2023, 307 patients who had undergone a median of three (IQR, 2-5) previous treatment regimens in the metastatic setting received SHR-A1811 treatment. As of data cutoff (February 28, 2023), one patient from the 6.4 mg/kg group experienced dose-limiting toxicities (pancytopenia and colitis). The most common grade 3 or higher adverse events (AEs) included decreased neutrophil count (119 [38.8%]) and decreased WBC count (70 [22.8%]). Interstitial lung disease occurred in only eight (2.6%) patients. Serious AEs and deaths occurred in 70 (22.8%) and 13 (4.2%) patients, respectively. SHR-A1811 led to objective responses in 59.9% (184/307) of all patients, 76.3% (90/118) of HER2-positive breast cancer, 60.4% (55/91) of HER2 low-expressing breast cancer, and 45.9% (39/85 with evaluable tumor responses) of the 98 nonbreast tumors. CONCLUSION SHR-A1811 exhibited acceptable tolerability, promising antitumor activity, and a favorable pharmacokinetic profile in heavily pretreated advanced solid tumors. The recommended phase II dose of 4.8 or 6.4 mg/kg was selected for various tumor types.
Tuning the photophysical properties of cyanine by barbiturate functionalization and nanoformulation for efficient optoacoustics- guided phototherapy
Authors: Nian Liu, Patrick O'Connor, Vipul Gujrati, Divyesh Shelar, Xiaopeng Ma, Pia Anzenhofer, Uwe Klemm, Xinhui Su, Yuanhui Huang, Karin Kleigrewe, Annette Feuchtinger, Axel Walch, Michael Sattler, Oliver Plettenburg, Vasilis Ntziachristos
Journal: Journal of Controlled Release (2024)

Cyanine derivatives are organic dyes widely used for optical imaging. However, their potential in longitudinal optoacoustic imaging and photothermal therapy remains limited due to challenges such as poor chemical stability, poor photostability, and low photothermal conversion. In this study, we present a new structural modification for cyanine dyes by introducing a strongly electron-withdrawing group (barbiturate), resulting in a new series of barbiturate-cyanine dyes (BC810, BC885, and BC1010) with suppressed fluorescence and enhanced stability. Furthermore, the introduction of BC1010 into block copolymers (PEG
Clinical remission with biologic therapies in severe asthma: a matter of definition
Authors: P. Jane McDowell, Ron McDowell, John Busby, M. Chad Eastwood, Pujan H. Patel, David J. Jackson, Adel Mansur, Mitesh Patel, Hassan Burhan, Simon Doe, Rekha Chaudhuri, Robin Gore, James W. Dodd, Deepak Subramanian, Thomas Brown, Liam G. Heaney
Journal: European Respiratory Journal (2024)

<h3>Shareable abstract</h3> <b>There is currently no evidence to support the use of maintenance and reliever therapy (MART) in patients with severe asthma and persistently elevated T2 biomarkers despite adherence to high dose ICS treatment</b>https://bit.ly/42IOVbA
New priorities for Croatia to pursue tuberculosis pre-elimination
Authors: Mateja Jankovic Makek, Zvjezdana Lovric Makaric, Goranka Petrovic, Gordan Sarajlic, Ljiljana Zmak, Rosella Centis, Lia D'Ambrosio, Giovanni Battista Migliori
Journal: European Respiratory Journal (2024)

<h3>Shareable abstract</h3> <b>To pursue tuberculosis (TB) pre-elimination, Croatia has to prioritise screening and treatment of TB infection across all at-risk groups, as well as a state-wide programme for active TB screening in foreign workers arriving from high TB burden countries</b>https://bit.ly/4b1UDse
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma
Authors: Richard Beasley, Jonathan Noble, Mark Weatherall
Journal: European Respiratory Journal (2024)

<h3>Shareable abstract</h3> <b>ICS/formoterol MART is an evidence-based alternative to high dose ICS/LABA in asthma patients at high risk of severe exacerbations; limited generalisability of RCTs to severe asthma registries applies similarly to high dose ICS/LABA therapy as to MART</b>https://bit.ly/4aVFrNH
Development and Validation of a Score to Assess Transmural Healing and Response in Patients with Crohn’s Disease
Authors: Anthony Buisson, Jérémy Junda, Jeanne Vignette, Emma Lecoq, Guillaume Bouguen, Felix Goutorbe, Julien Scanzi, Dilek Coban, Marie Dodel, Maëva Bazoge, Bruno Pereira, Constance Hordonneau
Journal: Clinical Gastroenterology and Hepatology (2024)
The ban on engineered stone in Australia: a milestone in the fight against emerging silica hazards
Authors: Catherine Cavalin, Alfredo Menéndez-Navarro, Antonio León-Jiménez, Valérie Lecureur, Alain Lescoat
Journal: European Respiratory Journal (2024)

<h3>Shareable abstract</h3> <b>Australia9s recent ban of engineered stone was based on sound scientific expertise and a democratic process. It highlights the toxicity of this material beyond its crystalline silica content, and raises awareness on a global and European health issue.</b>https://bit.ly/3QDYgMS
Presenting clinical data for the hazard classification of chemical respiratory sensitisers
Authors: Hille Suojalehto, Sandrine Charles-Poucel, Katri Suuronen, Steven Ronsmans, Jeroen Vanoirbeek, Benoit Nemery, Paul Cullinan
Journal: European Respiratory Journal (2024)

<h3>Shareable abstract</h3> <b>Preventing asthma caused by sensitising chemicals at work requires them to be identified and classified as hazardous. Accurate and unambiguous clinical and epidemiological data are essential in these processes.</b>https://bit.ly/3R7EhH1
Gastric peroral endoscopic myotomy mucosotomy closure using a novel hand suturing device
Authors: Pedro J. Rosón, Francisco Fernandez Cano, Mari A. Romero, Alicia Paris
Journal: Endoscopy (2024)

A 37-year-old patient with clinical signs of gastroparesis underwent a gastric peroral endoscopic pyloromyotomy (G-POEM) technique. After creating the submucosal tunnel and sectioning the pylorus, it was necessary to suture the gastric mucosotomy. Generally, this is done with standard endoscopic clips, but given that the gastric mucosa and muscular mucosa are thicker than the esophageal mucosa, it is sometimes difficult to close the mucosotomy, and in other cases early dehiscence of the closure has been described, requiring a second endoscopic closure [1].
Tracheomalacia and tracheomegaly in infants and children with congenital diaphragmatic hernia managed with and without fetoscopic endoluminal tracheal occlusion (FETO): a multicentre, retrospective cohort study
Authors: David Basurto, Kanokwaroon Watananirun, Anne-Gael Cordier, Juan Otaño, Diane Carriere, Marianna Scuglia, Anna Moraes de Luna Freire Vargas, Jordi Prat, Francesca Maria Russo, Anne Debeer, Cleisson Fábio Andrioli Peralta, Paolo De Coppi, Eduard Gratacós, Alexandra Benachi, Jan Deprest
Journal: The Lancet Child & Adolescent Health (2024)
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial
Authors: Feng Gao, Xu Tong, Baixue Jia, Ming Wei, Yuesong Pan, Ming Yang, Dapeng Sun, Thanh N Nguyen, Zeguang Ren, Francis Demiraj, Xiaoxi Yao, Chenghua Xu, Guangxiong Yuan, Yue Wan, Jianjun Tang, Jing Wang, Yuanfei Jiang, Chaobin Wang, Xiang Luo, Haihua Yang, Ruile Shen, Zhilin Wu, Zhengzhou Yuan, Dongjun Wan, Wei Hu, Yan Liu, Ping Jing, Liping Wei, Tuanyuan Zheng, Yingchun Wu, Xinguang Yang, Yaxuan Sun, Changming Wen, Mingze Chang, Bo Yin, Di Li, Jixin Duan, Dianjing Sun, Zaiyu Guo, Guodong Xu, Guoqing Wang, Liyu Wang, Yang Wang, Weihua Jia, Gaoting Ma, Xiaochuan Huo, Dapeng Mo, Ning Ma, Liping Liu, Xingquan Zhao, Yilong Wang, Jens Fiehler, Yongjun Wang, Zhongrong Miao
Journal: The Lancet Neurology (2024)
Hypoxaemia and risk of death among children: rethinking oxygen saturation, risk-stratification, and the role of pulse oximetry in primary care
Authors: Hamish R Graham, Carina King, Trevor Duke, Salahuddin Ahmed, Abdullah H Baqui, Tim Colbourn, Adegoke G Falade, Helena Hildenwall, Shubhada Hooli, Yewande Kamuntu, Rami Subhi, Eric D McCollum
Journal: The Lancet Global Health (2024)
Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies
Authors: Xiang Zhang, Zi‐Yi Li, Jia‐Heng Xiao, Peng‐Fei Hao, Juan Mo, Xiu‐Jing Zheng, Yi‐Qun Geng, Xin‐Shan Ye
Journal: Advanced Healthcare Materials (2024)

Immune checkpoint blockade (ICB) has significantly improved the prognosis of patients with cancer, although the majority of such patients achieve low response rates; consequently, new therapeutic approaches are urgently needed. The upregulation of sialic acid-containing glycans is a common characteristic of cancer-related glycosylation, which drives disease progression and immune escape via numerous pathways. Herein, the development of self-assembled core-shell nanoscale coordination polymer nanoparticles loaded with a sialyltransferase inhibitor, referred to as NCP-STI which effectively stripped diverse sialoglycans from cancer cells, providing an antibody-independent pattern to disrupt the emerging Siglec-sialic acid glyco-immune checkpoint is reported. Furthermore, NCP-STI inhibits sialylation of the concentrated nucleoside transporter 1 (CNT1), promotes the intracellular accumulation of anticancer agent gemcitabine (Gem), and enhances Gem-induced immunogenic cell death (ICD). As a result, the combination of NCP-STI and Gem (NCP-STI/Gem) evokes a robust antitumor immune response and exhibits superior efficacy in restraining the growth of multiple murine tumors and pulmonary metastasis. Collectively, the findings demonstrate a novel form of small molecule-based chemo-immunotherapy approach which features sialic acids blockade that enables cooperative effects of cancer cell chemosensitivity and antitumor immune responses for cancer treatment.
Plasma adiponectin levels in relation to chronic hepatitis B infection progression to liver cancer milestones: a Prospective study
Authors: Chi-Ling Chen, Wei-Shiung Yang, Hwai-I Yang, Chuen-Fei Chen, Li-Yu Wang, Sheng-Nan Lu, Jia-Horng Kao, Pei-Jer Chen, Chien-Jen Chen
Journal: Liver Cancer (2024)

Our previous nested-case-control study demonstrated elevated adiponectin increased liver cirrhosis and HCC risk in HBV carriers. We extended the analysis to the whole REVEAL-HBV cohort to prospectively evaluate whether adiponectin directly affected end-stage liver diseases, or through affecting HBV progression. Baseline plasma adiponectin was determined to investigate the association between adiponectin and subsequent HBeAg, HBsAg, and HBV DNA seroclearance, and the development of cirrhosis, HCC and liver-related death. Whether HBV characteristics modify the adiponectin-milestones associations was also examined. Among 3,931 HBsAg(+)/anti-HCV(-) REVEAL-HBV participants, 3,684 had sufficient biosamples left for adiponectin assay. Elevated adiponectin was associated with a higher chance of HBeAg-seropositive, high HBV viral load (≥2 × 105 IU/mL) and high HBsAg titers (≥1,000 IU/mL) in a dose-response manner (OR = 2.25, 95% CI: 1.55-3.28; OR = 2.11, 95% CI: 1.47-3.04; and OR = 1.92, 95% CI: 1.47-2.52 for Q5 vs. Q1, respectively). Those with the highest quintile had a lower chance of achieving HBeAg (HR = 0.48, 95% CI: 0.27-0.85), HBsAg (HR = 0.69, 95% CI: 0.49-0.97), and HBV DNA seroclearance (HR = 0.63, 95% CI: 0.43-0.90) and a higher chance of developing liver cirrhosis (HR = 2.88, 95% CI: 1.98-4.20, HCC (HR = 2.38, 95% CI: 1.52-3.73), and died from liver-related causes (HR = 2.32, 95% CI: 1.51-3.54). HBV genotype significantly modified the adiponectin-HCC (Pinteraction = 0.005) and adiponectin-liver death associations (Pinteraction = 0.0157), with higher risk among genotype C. Elevated adiponectin is consistently associated with all important chronic HBV infection milestones toward progression to liver cancer. The exact mechanism of how adiponectin mediates HBV infection toward carcinogenesis remains unclear and warrants further investigation. Disentangling this may help us in finding new HBV treatment target, biomarker in HBV surveillance to identify high-risk patients, or even cancer prevention.
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
Authors: Richard S Finn, Peter R Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Journal: Liver Cancer (2024)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (PVTT) and other high-risk prognostic factors are reported. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; IMbrave150 was a global, randomized (2:1), open-label, phase 3 study in systemic treatment–naive patients with unresectable HCC; OS and PFS were co-primary endpoints. Exploratory analyses compared the efficacy and safety of atezolizumab 1,200 mg plus bevacizumab 15 mg/kg every 3 weeks versus sorafenib 400 mg twice daily in patients (i) with and without Vp4 PVTT alone and (ii) with and without high-risk prognostic factors. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; In patients with Vp4 PVTT, median OS was 7.6 months (95% CI: 6.0–13.9) with atezolizumab plus bevacizumab (&lt;i&gt;n&lt;/i&gt; = 48) and 5.5 months (95% CI: 3.4–6.7) with sorafenib (&lt;i&gt;n&lt;/i&gt; = 25; HR 0.62 [95% CI: 0.34–1.11]; descriptive &lt;i&gt;p&lt;/i&gt; = 0.104). Median PFS in the respective arms was 5.4 months (95% CI: 3.6–6.9) and 2.8 months (95% CI: 1.5–5.3; HR 0.62 [95% CI: 0.35–1.09]; descriptive &lt;i&gt;p&lt;/i&gt; = 0.094). In patients without Vp4, median OS was 21.1 months (95% CI: 18.0–24.6) with atezolizumab plus bevacizumab (&lt;i&gt;n&lt;/i&gt; = 288) and 15.4 months (95% CI: 12.6–18.6) with sorafenib (&lt;i&gt;n&lt;/i&gt; = 140; HR 0.67 [95% CI: 0.51–0.88]; descriptive &lt;i&gt;p&lt;/i&gt; = 0.003). Median PFS in the respective arms was 7.1 months (95% CI: 6.1–9.6) and 4.7 months (95% CI: 4.2–6.1; HR 0.64 [95% CI: 0.51–0.81]; descriptive &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001). The high-risk versus non–high-risk populations had similar outcome patterns. In the respective treatment arms, grade ≥3 treatment-related adverse events occurred in 43% and 48% of patients with Vp4 and 46% and 47% of patients without Vp4. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; Regardless of VP4 PVTT or other high-risk features of unresectable HCC, which have often resulted in exclusion from other front-line trials, patients benefited from atezolizumab and bevacizumab versus sorafenib.
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias
Authors: Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst, Vineet Pande, Ann Marien, Dries Goffin, Daniela V. Wenge, Hong Yue, Jevon A. Cutler, Cyrus Jin, Florian Perner, Shanna M. Hogeling, Paul L. Shaffer, Frank Jacobs, Petra Vinken, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Balpreet Bhogal, Karin Verstraeten, Sara El Ashkar, Jennifer A. Perry, Prathiba Jayaguru, Laura Barreyro, Anna Kuchnio, Nicolas Darville, Daniel Krosky, Gregor Urbanietz, Bie Verbist, James P. Edwards, Glenn S. Cowley, Robert Kirkpatrick, Ruth Steele, Lucille Ferrante, Christina Guttke, Nikki Daskalakis, E. Christine Pietsch, David M. Wilson, Ricardo Attar, Yusri Elsayed, Eric S. Fischer, Jan Jacob Schuringa, Scott A. Armstrong, Kathryn Packman, Ulrike Philippar
Journal: Blood (2024)
GVHD targets organoid-forming bile duct stem cells via a TGF-β-dependent manner
Authors: Yuta Hasegawa, Daigo Hashimoto, Zixuan Zhang, Toru Miyajima, Yumika Saito, Wenyu Li, Ryo Kikuchi, Hajime Senjo, Tomoko Sekiguchi, Takahiro Tateno, Xuanzhong Chen, Emi Yokoyama, Shuichiro Takahashi, Hiroyuki Ohigashi, Takahide Ara, Eiko Hayase, Isao Yokota, Takanori Teshima
Journal: Blood (2024)
Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART) therapy in children and adolescents
Authors: Caroline Diorio, Laura Hernandez-Miyares, Diego A. Espinoza, Brenda L. Banwell, Amit Bar-Or, Amanda M. DiNofia, Allison Barz Leahy, Zachary Martinez, Regina M. Myers, Sarah E. Hopkins, Susan R. Rheingold, David T. Teachey, Angela N. Viaene, Lisa M. Wray, Shannon L. Maude, Stephan A. Grupp, Jennifer L. McGuire
Journal: Blood (2024)
Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort
Authors: Baruch Wolach, Ronit Gavrieli, Ofir Wolach, Pazit Salamon, Martin de Boer, Karin van Leeuwen, Omar Abuzaitoun, Arnon Broides, Giora Gottesman, Galia Grisaru-Soen, David Hagin, Nufar Marcus, Menachem Rottem, Yechiel Schlesinger, Tali Stauber, Polina Stepensky, Yael Dinur-Schejter, Tal Zeeli, Suheir Hanna, Amos Etzioni, Shirly Frizinsky, Raz Somech, Dirk Roos, Idit Lachover-Roth
Journal: Blood (2024)
Amino‐Acid‐Encoded Supramolecular Nanostructures for Persistent Bioluminescence Imaging of Tumor
Authors: Yifan Huang, Zian Yu, Jiancheng Peng, Qin Yu, Hao Xu, Miaomiao Yang, Sijie Yuan, Qianzijing Zhang, Yanyun Yang, Jin Gao, Yue Yuan
Journal: Advanced Healthcare Materials (2024)

Bioluminescence imaging (BLI) is a powerful technique for noninvasive monitoring of biological processes and cell transplantation. Nonetheless, the application of D-luciferin, which is widely employed as a bioluminescent probe, is restricted in long-term in vivo tracking due to its short half-life. This study presents a novel approach using amino acid-encoded building blocks to accumulate and preserve luciferin within tumor cells, through a supramolecular self-assembly strategy. The building block platform called Cys(SEt)-X-CBT (CXCBT, with X representing any amino acid) utilizes a covalent-noncovalent hybrid self-assembly mechanism to generate diverse luciferin-containing nanostructures in tumor cells after glutathione reduction. These nanostructures exhibit efficient tumor-targeted delivery as well as sequence-dependent well-designed morphologies and prolonged bioluminescence performance. Among the selected amino acids (X = Glu, Lys, Leu, Phe), Cys(SEt)-Lys-CBT (CKCBT) exhibits the superior long-lasting bioluminescence signal (up to 72 h) and good biocompatibility. This study demonstrates the potential of amino-acid-encoded supramolecular self-assembly as a convenient and effective method for developing BLI probes for long-term biological tracking and disease imaging.
Long-term outcomes of ablation versus surgery in patients with colorectal lung oligometastasis: A retrospective cohort study.
Authors: Tian-Qi Zhang, Yu-Zhe Cao, Xin Zheng, Wei-Jun Fan, Pei-Hong Wu, Jin-Hua Huang
Journal: Journal of Clinical Oncology (2024)

3581 Background: Lung is the common metastatic site of colorectal carcinoma. Treatment of colorectal lung oligometastasis (CLOM) by surgical and ablative procedures has been proved to prolong survival and palliate symptoms. We aimed to analyze the long-term outcomes of patients with CLOM treated with surgery or ablation. Methods: From January 2012 to October 2018, patients diagnosed with CLOM that underwent surgery or ablation at the Sun Yat-sen University Cancer Center were retrospectively analyzed. Results: The study included 96 patients with 134 lesions, including 25 females (26.0%) and 71 males (74.0%). All the patients had received the primary colorectal lesion resection before treatment of metastasis. There were 41 patients with 75 lesions receiving ablation and 55 patients with 59 lesions receiving surgery. The median follow-up time was 58.3 months (IQR: 38.6-73.7). The median overall survivals (mOS), 3- and 5-year survival rates between the two groups showed no significant difference (Ablation vs. Surgery, mOS: 73.3 months vs 70.4 months, P=0.64; 3-year survival rate: 82.6% vs. 79.8%; 5-year survival rate: 59.9% vs. 58.7%. The median progression-free survivals (mPFS) were 12.1 months in the ablation group and 11.5 months in the surgery group (P=0.48), respectively. Local rates of recurrence per lesion were 26.7% and 22.0% (P=0.68). And the pulmonary mPFS were 14.5 months vs. 14.1 months (P=0.95). Conclusions: Our retrospective cohort data showed that there was no significant difference between surgery and ablation in long-term survival benefit to CLOM patients. [Table: see text]